{"transactions":[{"id":2217441,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-07-01T16:31:58.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":12000,"derivative":{"underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001628280-22-018349","document":"wf-form4_165669310580119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000162828022018349/wf-form4_165669310580119.xml","form_type":"4"}},{"id":2217440,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:31:58.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":7000,"derivative":{"exercise_price":12.89,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001628280-22-018349","document":"wf-form4_165669310580119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000162828022018349/wf-form4_165669310580119.xml","form_type":"4"}},{"id":2228113,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-17T20:51:24.000Z","date":"2022-06-15","kind":"exercise","acquired":false,"shares":4257,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"RSUs granted on June 15, 2021 in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs granted on June 15, 2021 in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4257},"source":{"system":"sec-edgar","filing":"0001209191-22-037924","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919122037924/doc4.xml","form_type":"4"}},{"id":2228112,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-17T20:51:24.000Z","date":"2022-06-15","kind":"exercise","acquired":true,"shares":4257,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\").  Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\").  Each RSU represents a contingent right to receive one share of the Company's common stock."}],"balance_after":1208273,"source":{"system":"sec-edgar","filing":"0001209191-22-037924","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919122037924/doc4.xml","form_type":"4"}},{"id":2277983,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-09T20:42:24.000Z","date":"2022-05-05","kind":"purchase","acquired":true,"shares":100000,"price":13.5,"value":1350000.0,"ownership":{"direct":false,"nature":"By the Ackermann & Elmen-Gruys Trust Dated June 24, 2014"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person purchased the shares of common stock reported hereby from the underwriters in an underwritten public offering conducted by the Issuer pursuant to an underwriting agreement, dated May 2, 2022, between the Issuer and the representatives of the several underwriters. Each share of common stock was sold by the underwriters at a price of $13.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the trustee of the Ackermann & Elmen-Gruys Trust Dated June 24, 2014 and has voting and dispositive power with respect to these shares."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001209191-22-027856","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919122027856/doc4.xml","form_type":"4"}},{"id":2486316,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T23:56:58.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":528,"price":26.65,"value":14071.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.53 to $27.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1204016,"source":{"system":"sec-edgar","filing":"0001819790-21-000059","document":"wf-form4_163857580594057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979021000059/wf-form4_163857580594057.xml","form_type":"4"}},{"id":2486315,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T23:56:58.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":809,"price":25.87,"value":20928.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.51 to $26.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1204544,"source":{"system":"sec-edgar","filing":"0001819790-21-000059","document":"wf-form4_163857580594057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979021000059/wf-form4_163857580594057.xml","form_type":"4"}},{"id":2486314,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T23:56:58.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":2054,"price":24.68,"value":50692.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $24.28 to $25.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1205353,"source":{"system":"sec-edgar","filing":"0001819790-21-000059","document":"wf-form4_163857580594057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979021000059/wf-form4_163857580594057.xml","form_type":"4"}},{"id":2486313,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T23:56:58.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":2442,"price":23.85,"value":58241.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $23.24 to $24.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1207407,"source":{"system":"sec-edgar","filing":"0001819790-21-000059","document":"wf-form4_163857580594057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979021000059/wf-form4_163857580594057.xml","form_type":"4"}},{"id":2526606,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:00:18.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":869,"price":28.18,"value":24488.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $28.11 to $28.27. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1209849,"source":{"system":"sec-edgar","filing":"0001819790-21-000043","document":"wf-form4_163598040275686.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979021000043/wf-form4_163598040275686.xml","form_type":"4"}},{"id":2526605,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:00:18.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":4964,"price":27.76,"value":137800.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $27.10 to $28.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1210718,"source":{"system":"sec-edgar","filing":"0001819790-21-000043","document":"wf-form4_163598040275686.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979021000043/wf-form4_163598040275686.xml","form_type":"4"}},{"id":2542501,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-14T20:48:29.000Z","date":"2021-10-12","kind":"sale","acquired":false,"shares":4517,"price":26.45,"value":119474.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.12 to $26.93. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1215682,"source":{"system":"sec-edgar","filing":"0001819790-21-000039","document":"wf-form4_163424449168205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979021000039/wf-form4_163424449168205.xml","form_type":"4"}},{"id":2542500,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-14T20:48:29.000Z","date":"2021-10-12","kind":"sale","acquired":false,"shares":1116,"price":25.56,"value":28524.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $25.08 to $26.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1220199,"source":{"system":"sec-edgar","filing":"0001819790-21-000039","document":"wf-form4_163424449168205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979021000039/wf-form4_163424449168205.xml","form_type":"4"}},{"id":2544625,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-12T22:47:37.000Z","date":"2021-10-08","kind":"sale","acquired":false,"shares":200,"price":25.03,"value":5006.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $25.000 to $25.06, inclusive. The Reporting Person undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1221315,"source":{"system":"sec-edgar","filing":"0001819790-21-000035","document":"wf-form4_163407884464685.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979021000035/wf-form4_163407884464685.xml","form_type":"4"}},{"id":2579673,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T22:53:56.000Z","date":"2021-09-01","kind":"sale","acquired":false,"shares":5833,"price":25.242,"value":147236.586,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $25.000 to $25.970, inclusive. The Reporting Person undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1221515,"source":{"system":"sec-edgar","filing":"0001209191-21-054888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919121054888/doc4.xml","form_type":"4"}},{"id":2605606,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-12T21:27:31.000Z","date":"2021-08-11","kind":"sale","acquired":false,"shares":621,"price":25.152,"value":15619.392,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $25.030 to $25.250, inclusive. The Reporting Person undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1227348,"source":{"system":"sec-edgar","filing":"0001209191-21-051193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919121051193/doc4.xml","form_type":"4"}},{"id":2608691,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-10T20:55:05.000Z","date":"2021-08-09","kind":"sale","acquired":false,"shares":700,"price":25,"value":17500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."}],"balance_after":1227969,"source":{"system":"sec-edgar","filing":"0001209191-21-050631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919121050631/doc4.xml","form_type":"4"}},{"id":2608690,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-10T20:55:05.000Z","date":"2021-08-06","kind":"sale","acquired":false,"shares":3129,"price":25,"value":78225.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."}],"balance_after":1228669,"source":{"system":"sec-edgar","filing":"0001209191-21-050631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919121050631/doc4.xml","form_type":"4"}},{"id":2611752,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-06T20:16:03.000Z","date":"2021-08-05","kind":"sale","acquired":false,"shares":100,"price":25.01,"value":2501.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."}],"balance_after":1231798,"source":{"system":"sec-edgar","filing":"0001209191-21-050177","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919121050177/doc4.xml","form_type":"4"}},{"id":2611751,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-06T20:16:03.000Z","date":"2021-08-05","kind":"sale","acquired":false,"shares":100,"price":25.005,"value":2500.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."}],"balance_after":1231898,"source":{"system":"sec-edgar","filing":"0001209191-21-050177","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919121050177/doc4.xml","form_type":"4"}},{"id":2611750,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-06T20:16:03.000Z","date":"2021-08-05","kind":"sale","acquired":false,"shares":1183,"price":25,"value":29575.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021."}],"balance_after":1231998,"source":{"system":"sec-edgar","filing":"0001209191-21-050177","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919121050177/doc4.xml","form_type":"4"}},{"id":2664115,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-17T23:19:00.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":4257,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":4257,"derivative":{"underlying":"Common Stock","underlying_shares":4257},"source":{"system":"sec-edgar","filing":"0001209191-21-041701","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919121041701/doc4.xml","form_type":"4"}},{"id":2664114,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T23:19:00.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested."}],"balance_after":10000,"derivative":{"exercise_price":35.26,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-041701","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919121041701/doc4.xml","form_type":"4"}},{"id":2664113,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T23:19:00.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":10000,"derivative":{"exercise_price":35.26,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-041701","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919121041701/doc4.xml","form_type":"4"}},{"id":2664112,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-17T23:19:00.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":4257,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The RSUs are fully vested as of the date of grant."}],"balance_after":1233181,"source":{"system":"sec-edgar","filing":"0001209191-21-041701","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919121041701/doc4.xml","form_type":"4"}},{"id":3003135,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-10-20T23:54:48.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":9246,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9246},"source":{"system":"sec-edgar","filing":"0001209191-20-055420","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055420/doc4.xml","form_type":"4"}},{"id":3003134,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-10-20T23:54:48.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":53939,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":53939},"source":{"system":"sec-edgar","filing":"0001209191-20-055420","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055420/doc4.xml","form_type":"4"}},{"id":3003133,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T23:54:48.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":9246,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."}],"balance_after":1228924,"source":{"system":"sec-edgar","filing":"0001209191-20-055420","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055420/doc4.xml","form_type":"4"}},{"id":3003132,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T23:54:48.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":53939,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."}],"balance_after":1219678,"source":{"system":"sec-edgar","filing":"0001209191-20-055420","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055420/doc4.xml","form_type":"4"}},{"id":3114240,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-10T21:12:39.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":14805,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares underlying the RSU vest as to one-twelfth (1/12th) of the RSU on July 8, 2020 and monthly thereafter on the same day of the month as the grant date; however, the shares underlying the RSU will vest fully on the date of the next annual stockholder meeting held after the date of grant if not fully vested on such date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date."}],"balance_after":152162,"source":{"system":"sec-edgar","filing":"0001209191-20-035746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720725/000120919120035746/doc4.xml","form_type":"4"}},{"id":3381642,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-11-04T17:47:54.000Z","date":"2019-11-04","kind":"exercise","acquired":false,"shares":140567,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held through a trust, the sole trustee of which is the Reporting Person and the sole beneficiaries of which are immediate family members of the Reporting Person, including the Reporting Person."}],"balance_after":0,"derivative":{"underlying":"Common Stock, par value $0.001 per share","underlying_shares":140567},"source":{"system":"sec-edgar","filing":"0000899243-19-026590","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720725/000089924319026590/doc4.xml","form_type":"4"}},{"id":3381641,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":125714,"kind":"person","name":"Ackermann Michael","position":1,"cik":"0001791249","reported_name":"Ackermann Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2019-11-04T17:47:54.000Z","date":"2019-11-04","kind":"exercise","acquired":true,"shares":140567,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held through a trust, the sole trustee of which is the Reporting Person and the sole beneficiaries of which are immediate family members of the Reporting Person, including the Reporting Person."}],"balance_after":140567,"source":{"system":"sec-edgar","filing":"0000899243-19-026590","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720725/000089924319026590/doc4.xml","form_type":"4"}}]}